SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) – Equities researchers at Wedbush increased their FY2027 earnings estimates for SpringWorks Therapeutics in a research report issued on Wednesday, August 28th. Wedbush analyst D. Nierengarten now expects that the company will earn $3.56 per share for the year, up from their previous estimate of $3.41. Wedbush has a “Outperform” rating and a $77.00 price target on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.34) per share.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.58. The company had revenue of $59.73 million for the quarter, compared to analyst estimates of $34.42 million. During the same period last year, the company posted ($1.25) EPS. The business’s revenue for the quarter was up 59732900.0% on a year-over-year basis.
View Our Latest Stock Report on SpringWorks Therapeutics
SpringWorks Therapeutics Stock Performance
Shares of SWTX stock opened at $41.71 on Thursday. SpringWorks Therapeutics has a one year low of $18.00 and a one year high of $53.92. The company has a 50 day moving average price of $37.72 and a 200 day moving average price of $42.60. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -8.11 and a beta of 0.78.
Institutional Investors Weigh In On SpringWorks Therapeutics
Several institutional investors have recently bought and sold shares of the business. Quarry LP grew its stake in SpringWorks Therapeutics by 56.3% during the second quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $188,000 after buying an additional 1,800 shares during the period. Algert Global LLC boosted its stake in shares of SpringWorks Therapeutics by 62.7% in the second quarter. Algert Global LLC now owns 34,989 shares of the company’s stock valued at $1,318,000 after purchasing an additional 13,489 shares during the period. Maverick Capital Ltd. boosted its stake in shares of SpringWorks Therapeutics by 36.3% in the second quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company’s stock valued at $97,962,000 after purchasing an additional 691,894 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in shares of SpringWorks Therapeutics by 16.9% in the second quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company’s stock valued at $28,581,000 after purchasing an additional 109,865 shares during the period. Finally, Duquesne Family Office LLC purchased a new position in shares of SpringWorks Therapeutics in the second quarter valued at $38,475,000.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Further Reading
- Five stocks we like better than SpringWorks Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- What is an Earnings Surprise?
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- What is the S&P 500 and How It is Distinct from Other Indexes
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.